Structure Therapeutics (GPCR) Other Accumulated Expenses (2022 - 2026)

Structure Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 221.24% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 221.24% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 73.55% from the prior year.
• Other Accumulated Expenses improved to $8.3 million in Q1 2026 per GPCR's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $9.7 million in Q2 2025 and bottomed at $1.2 million in Q1 2024.
• The 5-year median for Other Accumulated Expenses is $3.0 million (2024), against an average of $3.8 million.
• Across the five-year window, Other Accumulated Expenses slumped 73.55% in 2025 and soared 221.24% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.8 million in 2022, then jumped by 159.57% to $4.7 million in 2023, then advanced by 15.7% to $5.5 million in 2024, then slumped by 73.55% to $1.4 million in 2025, then surged by 478.19% to $8.3 million in 2026.
• Per Business Quant, the three latest GPCR Other Accumulated Expenses figures stand at $8.3 million (Q1 2026), $1.4 million (Q4 2025), and $6.6 million (Q3 2025).